Plasma levels of natriuretic peptides and development of chronic kidney disease

BMC Nephrology

Johji Kato¹  Kazuo Kitamura³  Kenji Kuwasako¹  Hiroshi Komura³  Noriyuki Ogawa² 

[1]Frontier Science Research Center, University of Miyazaki, 5200 Kihara, Kiyotake 889-1692, Miyazaki, Japan

[2]Department of Occupational Therapy, Kyushu University of Health and Welfare School of Health and Science, Nobeoka 882-8508, Miyazaki, Japan

[3]Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Kiyotake 889-1692, Miyazaki, Japan

关键词: Plasma level;    General population;    Chronic kidney disease;    Natriuretic peptides;   

Others  :  1231145
DOI  :  10.1186/s12882-015-0163-9

 received in 2015-06-09, accepted in 2015-10-13,  发布年份 2015

【 摘 要 】

Background

Plasma levels of atrial and brain natriuretic peptides (ANP and BNP) are increased in patients with chronic kidney disease (CKD) complicated with deteriorated kidney function, but the relationship between the plasma level of ANP or BNP and the future development of CKD is unclear.

Methods

We measured the plasma ANP and BNP levels of 294 local residents without CKD in a Japanese community (56.5 ± 10.4 years, mean ± S.D.), who were followed up for the development of CKD over the next 7 years.

Results

Sixty-three residents developed CKD during the follow-up period, and the baseline level of plasma ANP of these residents was significantly higher than in those without CKD development. Kaplan-Meier analysis showed that the residents with higher ANP than the median value developed CKD more frequently than those with lower ANP. The association between plasma ANP level and CKD development was found to be independent of baseline estimated glomerular filtration rate by a Cox proportional hazards model, while this association became insignificant when adjusted by age; plasma ANP was significantly correlated with age. Compared with ANP, the relationship between plasma BNP and CKD development was unclear in these analyses.

Conclusions

Age-related elevation of plasma ANP levels preceded the development of CKD in the general population of Japan, raising a possibility for ANP being involved in the development of CKD.

【 授权许可】

   
2015 Ogawa et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun. 1984; 118:131-9.
• [2]Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988; 332(6159):78-81.
• [3]Ogawa T, de Bold AJ. The heart as an endocrine organ. Endocr Connect. 2014; 3:R31-44.
• [4]Minamino N, Nishikimi T. Natriuretic peptides. In: Handbook of biologically active peptides. Kastin AJ, editor. Academic, San Diego; 2013: p.1415-22.
• [5]Kato J, Eto T. Natriuretic peptides. In: Encyclopedia of endocrine diseases. Martini L, editor. Academic, San Diego; 2004: p.287-90.
• [6]Kato J.. Reference module in biomedical sciences. Caplan M, editor. Elsevier, London; 2014. [10.1016/B978-0-12-801238-3.03972-6] webcite
• [7]Tripathi S, Pandey KN. Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes the vascular endothelial growth factor-stimulated MAPKs and downstream effectors AP-1 and CREB in mouse mesangial cells. Mol Cell Biochem. 2012; 368:47-59.
• [8]Ogawa Y, Mukoyama M, Yokoi H, Kasahara M, Mori K, Kato Y, Kuwabara T, Imamaki H, Kawanishi T, Koga K, Ishii A, Tokudome T, Kishimoto I, Sugawara A, Nakao K. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol. 2012; 23:1198-209.
• [9]Kasahara M, Mukoyama M, Sugawara A, Makino H, Suganami T, Ogawa Y, Nakagawa M, Yahata K, Goto M, Ishibashi R, Tamura N, Tanaka I, Nakao K. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol. 2000; 11:1691-701.
• [10]Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, Akimoto K, Hattori Y, Kasai K, Minamino N, Maeda N, Matsuoka H. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept. 2009; 154:44-53.
• [11]Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010; 170:507-14.
• [12]Yandle TG, Espiner EA, Nicholls MG, Duff H. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab. 1986; 63:72-9.
• [13]Ishizaka Y, Yamamoto Y, Fukunaga T, Yokota N, Kida O, Kitamura K, Kangawa K, Minamino N, Matsuo H, Eto T. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis. 1994; 24:461-72.
• [14]Spanaus KS, Kronenberg F, Ritz E, Schlapbach R, Fliser D, Hersberger M, Kollerits B, König P, von Eckardstein A. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the mild-to-moderate kidney disease study. Clin Chem. 2007; 53:1264-72.
• [15]Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, Haltmayer M, Kronenberg F. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD study. Kidney Int. 2009; 75:408-14.
• [16]Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, Ferro CJ, Vickery S, Ayrton P, Nair D, Dalton RN, Lamb EJ, Baigent C, Townend JN, Wheeler DC. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis. 2010; 56:1082-94.
• [17]Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, Levey AS, Lewis EF, McMurray JJ, Parving HH, Solomon SD, Pfeffer MA. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011; 58:717-28.
• [18]Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010; 21:2143-9.
• [19]Bansal N, Katz R, Dalrymple L, de Boer I, DeFilippi C, Kestenbaum B, Park M, Sarnak M, Seliger S, Shlipak M. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults. Clin J Am Soc Nephrol. 2015; 10:205-14.
• [20]Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53:982-92.
• [21]Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994; 90:195-203.
• [22]Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, Kangawa K, Eto T. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res. 1999; 22:61-5.
• [23]Giannessi D, Andreassi MG, Del Ry S, Clerico A, Colombo MG, Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest. 2001; 24:8-16.
• [24]Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Kimura H, Shiono M, Takayama T, Hirayama A. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol. 2011; 58:897-903.
• [25]Ng TM, Ackerbauer KA, Hyderi AF, Hshieh S, Elkayam U. Comparative effects of nesiritide and nitroglycerin on renal function, and incidence of renal injury by traditional and RIFLE criteria in acute heart failure. J Cardiovasc Pharmacol Ther. 2012; 17:79-85.
• [26]McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993-1004.
• [27]Judge P, Haynes R, Landray MJ, Baigent C. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant. 2015; 30:738-43.